Tumour infiltrating lymphocytes and survival after adjuvant chemotherapy in patients with gastric cancer: post-hoc analysis of the CLASSIC trial.

Autor: Liu, Drolaiz H. W., Kim, Young-Woo, Sefcovicova, Nina, Laye, Jon P., Hewitt, Lindsay C., Irvine, Andrew F., Vromen, Vincent, Janssen, Yannick, Davarzani, Naser, Fazzi, Gregorio E., Jolani, Shahab, Melotte, Veerle, Magee, Derek R., Kook, Myeong-Cherl, Kim, Hyunki, Langer, Rupert, Cheong, Jae-Ho, Grabsch, Heike I.
Zdroj: British Journal of Cancer; Jun2023, Vol. 128 Issue 12, p2318-2325, 8p
Abstrakt: Background: Only a subset of gastric cancer (GC) patients with stage II–III benefits from chemotherapy after surgery. Tumour infiltrating lymphocytes per area (TIL density) has been suggested as a potential predictive biomarker of chemotherapy benefit. Methods: We quantified TIL density in digital images of haematoxylin-eosin (HE) stained tissue using deep learning in 307 GC patients of the Yonsei Cancer Center (YCC) (193 surgery+adjuvant chemotherapy [S + C], 114 surgery alone [S]) and 629 CLASSIC trial GC patients (325 S + C and 304 S). The relationship between TIL density, disease-free survival (DFS) and clinicopathological variables was analysed. Results: YCC S patients and CLASSIC S patients with high TIL density had longer DFS than S patients with low TIL density (P = 0.007 and P = 0.013, respectively). Furthermore, CLASSIC patients with low TIL density had longer DFS if treated with S + C compared to S (P = 0.003). No significant relationship of TIL density with other clinicopathological variables was found. Conclusion: This is the first study to suggest TIL density automatically quantified in routine HE stained tissue sections as a novel, clinically useful biomarker to identify stage II–III GC patients deriving benefit from adjuvant chemotherapy. Validation of our results in a prospective study is warranted. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: